Peptide compounding in 503A pharmacies and 503B outsourcing facilities demands precise vial size selection to achieve target concentrations (1-5 mg/mL) while maintaining sterility assurance levels, chemical stability, and beyond-use dating per USP 797 Category 2 requirements. Inappropriate vial capacity can lead to reconstitution calculation errors, insufficient headspace for mixing, syringe dead space losses exceeding ±10% of dosing accuracy, or benzyl alcohol preservative dilution below the 0.9% antimicrobial threshold—each of which could result in potential FDA 483 observations during inspections.
This technical guide equips compounding pharmacists, sterile compounding technicians, process engineers, and quality assurance professionals with standardized vial selection criteria, validated dilution mathematics, headspace validation protocols, and practical implementation workflows aligned with USP 697 Pharmaceutical Compounding – Containers, USP 660 glass standards, and ISO 8362-1-dimensional specifications. Read More >
